GR3032388T3 - The use of psoralen compounds to inhibit restenosis following angioplasty. - Google Patents

The use of psoralen compounds to inhibit restenosis following angioplasty.

Info

Publication number
GR3032388T3
GR3032388T3 GR990401780T GR990401780T GR3032388T3 GR 3032388 T3 GR3032388 T3 GR 3032388T3 GR 990401780 T GR990401780 T GR 990401780T GR 990401780 T GR990401780 T GR 990401780T GR 3032388 T3 GR3032388 T3 GR 3032388T3
Authority
GR
Greece
Prior art keywords
photopheresis
patient
blood
affected tissue
restenosis following
Prior art date
Application number
GR990401780T
Other languages
English (en)
Inventor
Emil Bisaccia
Albert S Klainer
Original Assignee
Emil Bisaccia
Albert S Klainer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emil Bisaccia, Albert S Klainer filed Critical Emil Bisaccia
Publication of GR3032388T3 publication Critical patent/GR3032388T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Details Of Rigid Or Semi-Rigid Containers (AREA)
GR990401780T 1991-12-17 1999-07-07 The use of psoralen compounds to inhibit restenosis following angioplasty. GR3032388T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/809,590 US5284869A (en) 1991-12-17 1991-12-17 Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty
PCT/US1992/010982 WO1993011657A2 (en) 1991-12-17 1992-12-17 The use of psoralen compounds to inhibit restenosis following angioplasty

Publications (1)

Publication Number Publication Date
GR3032388T3 true GR3032388T3 (en) 2000-05-31

Family

ID=25201702

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990401780T GR3032388T3 (en) 1991-12-17 1999-07-07 The use of psoralen compounds to inhibit restenosis following angioplasty.

Country Status (9)

Country Link
US (2) US5284869A (el)
EP (1) EP0661920B1 (el)
AT (1) ATE178757T1 (el)
AU (2) AU3328393A (el)
DE (1) DE69228952T2 (el)
DK (1) DK0661920T3 (el)
ES (1) ES2131572T3 (el)
GR (1) GR3032388T3 (el)
WO (1) WO1993011657A2 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284869A (en) * 1991-12-17 1994-02-08 Emil Bisaccia Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty
US5116864A (en) * 1991-04-09 1992-05-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994026303A1 (en) * 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
ATE377418T1 (de) 1995-06-07 2007-11-15 Poniard Pharmaceuticals Inc Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
US6008211A (en) * 1995-07-27 1999-12-28 Pdt Pharmaceuticals, Inc. Photoactivatable compounds comprising benzochlorin and furocoumarin
US5902299A (en) * 1997-07-29 1999-05-11 Jayaraman; Swaminathan Cryotherapy method for reducing tissue injury after balloon angioplasty or stent implantation
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
WO2000041726A2 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
DE60024114T2 (de) * 1999-09-24 2006-08-03 Vasogen Ireland Ltd., Shannon Zusammensetzung zur behandlung von atherosklerose, welche ein statin und ex-vivo behandeltes blut enthält
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7479123B2 (en) 2002-03-04 2009-01-20 Therakos, Inc. Method for collecting a desired blood component and performing a photopheresis treatment
US8109981B2 (en) * 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
WO2007106856A2 (en) * 2006-03-14 2007-09-20 Allux Medical, Inc. Phototherapy device and method of providing phototherapy to a body surface
US20070219600A1 (en) * 2006-03-17 2007-09-20 Michael Gertner Devices and methods for targeted nasal phototherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321919A (en) * 1979-12-11 1982-03-30 Leukocyte Research, Inc. Method and system for externally treating human blood
US4683889A (en) * 1983-03-29 1987-08-04 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US5284869A (en) * 1991-12-17 1994-02-08 Emil Bisaccia Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty
US5116864A (en) * 1991-04-09 1992-05-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels

Also Published As

Publication number Publication date
DK0661920T3 (da) 1999-10-25
AU3328393A (en) 1993-07-19
EP0661920B1 (en) 1999-04-14
DE69228952T2 (de) 1999-10-21
EP0661920A1 (en) 1995-07-12
DE69228952D1 (de) 1999-05-20
ES2131572T3 (es) 1999-08-01
US5284869A (en) 1994-02-08
ATE178757T1 (de) 1999-04-15
US5426116A (en) 1995-06-20
AU3688497A (en) 1997-12-18
WO1993011657A2 (en) 1993-06-24
EP0661920A4 (en) 1995-03-02

Similar Documents

Publication Publication Date Title
GR3032388T3 (en) The use of psoralen compounds to inhibit restenosis following angioplasty.
US5514707A (en) Inhibition of smooth muscle cell proliferation by 8-methoxypsoralen photoactivated by visible light
EP0579784B1 (en) Method for preventing restenosis following reconfiguration of body vessels
KR100256853B1 (ko) 혈관 내막과 형성 증진을 억제하기위한 약제학적 조성물
DE69201948T2 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
EP0295280B1 (en) Use of protoporphyrin and tin mesoporphyrin for the manufacture of a medicament for the treatment of psoriasis
DE59606784D1 (de) Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität
CA2295572A1 (en) Treatment of inflammatory disorders of the bowel and urinary bladder
DE59307982D1 (de) Verwendung von NADH und NADPH zur Herstellung eines Arzneimittels zur Behandlung von Morbus Alzheimer
CA2270558A1 (en) Treatment of autoimmune diseases by photochemotherapy
Chahidi et al. Photosensitization by methotrexate photoproducts
CA2117330C (en) The use of psoralen compounds to inhibit restenosis following angioplasty
Hull et al. Effect of hematoporphyrin derivative on rabbit corneal endothelial cell function and ultrastructure.
AU753208B2 (en) The use of psoralen compounds to inhibit restenosis following angioplasty
Sobeh et al. Photodynamic therapy in a cell culture model of human intimal hyperplasia
ATE235252T1 (de) Methode zur verminderung arterieller stenose
US4939167A (en) Use of 5-methoxypsoralen and other furocoumarins as jet lag suppressants
Sumpio et al. Inhibition of smooth muscle cell proliferation by visible light-activated psoralen.
Debta et al. Photochemotherapy (PUVA): an overview
Tanew Towards an improvement of photochemotherapy
UA10221A (uk) Спосіб лікування рецидивного бронхіту у дітей
DE69411833D1 (de) Verwendung von Chinonen zur Herstellung eines Arzneimittels zur Vorbeugung und Behandlung von allergischer Rhinitis
Yang et al. Treating esophagus-cardiac carcinoma by YAG laser gasifying with irradiating of hemoporphyrin derivative laser: additional analyses of 110 cases
MX9702985A (es) Endoprotesis temporal de flujo pasante emisora de radiacion.